TacticScaleWhat Boston Scientific Does & How It Makes Money (BSX)
Updated October 2026 · reflects Boston Scientific's latest reported financials
Medical device maker for heart, digestive, urology and nerve treatments. It makes money by selling medical devices, implants and systems to hospitals and physicians worldwide through two segments, MedSurg and Cardiovascular.
How Boston Scientific makes money
It makes money by selling medical devices, implants and systems to hospitals and physicians worldwide through two segments, MedSurg and Cardiovascular. Revenue comes from single-use products such as stents, catheters and disposable scopes, plus implantable devices like defibrillators, pacemakers and neurostimulators.
What Boston Scientific does
Boston Scientific, incorporated in 1979, is a global maker of medical devices used in interventional medicine. It reports two segments. MedSurg covers devices for gastrointestinal conditions (clips, biliary stents, the SpyGlass system, single-use duodenoscopes), urology (ureteral stents, digital ureteroscopes, laser systems, penile implants, artificial urinary sphincters), and neuromodulation for chronic pain and movement disorders (spinal cord stimulators, radiofrequency and intraosseous nerve ablation, deep brain stimulation). The Cardiovascular segment includes the WATCHMAN FLX left atrial appendage closure device, implantable defibrillators and pacemakers, S-ICD systems, insertable and remote cardiac monitors, and technologies for heart rhythm disorders and peripheral arterial and venous disease. It also sells products to diagnose and treat certain cancers. Its broad mix of single-use products and implantable therapies gives it exposure to many specialties across hospitals worldwide.
Products & services
- WATCHMAN FLX left atrial appendage closure device
- SpyGlass single-use scope system
- Implantable cardioverter defibrillators and S-ICD systems
- Spinal cord stimulator and deep brain stimulation systems
- Ureteral stents and single-use digital ureteroscopes
- Insertable and remote cardiac monitoring systems
What is Boston Scientific worth?
On an owner-earnings DCF, Boston Scientific's most-likely value is about $99 versus a recent price near $43 (133% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~$28) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Medtronic (MDT) · Becton, Dickinson and (BDX) · Edwards Lifesciences (EW) · Bruker (BRKR) · Merit Medical Systems (MMSI)